The PACIFICA study aimed to assess the efficacy and safety of pacritinib versus physician’s choice therapy in patients with myelofibrosis and severe thrombocytopenia. In this touchONCOLOGY interview, we speak with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) to discuss the aims, design and eligibility criteria of the PACIFICA study, and when the data is expected.
The abstract entitled ‘PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia’ (Abstract #4316) was presented at ASH Annual Meeting, 10–13, December, 2022.
Questions:
- What were the aims, design and eligibility criteria of the PACIFICA study? (0:16)
- What are the primary and secondary endpoints of the study? (2:23)
- When will data be available? (2:48)
Disclosures: John Mascarenhas is a consultant for Abbvie, BMS, CTi Bio, Galecto, GSK, Incyte Roche, Kartos, Karyopharm, Morphosys, Novartis and PharmaEssentia. He has received grant/research support from Abbvie, BMS, CTI, Incyte, Kartos, Novartis and PharmaEssentia.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ASH 2022
Access more content on Haematological Malignancies and Leukaemia
